Pressure Biosciences (PBIO) AI Stock Analysis

• Market Cap: $16.39K
• Dividend Yield: N/A
• Average Volume (3M): 1.38K
• Price to Earnings (P/E): ―
• Beta (1Y): -3.95
• Revenue Growth: -20.28%
• EPS Growth: 13.56%
• Country: US
• Employees: 15
• Sector: Healthcare
• Sector Strength: 40
• Industry: Medical - Devices
• EPS (TTM): -0.95
• Shares Outstanding: 40,967,083
• 10 Day Avg. Volume: 50
• 30 Day Avg. Volume: 1,381
• PEG Ratio: >-0.01
• Price to Book (P/B): >-0.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: >-0.01
• Enterprise Value/Market Cap: 1.78K
• Enterprise Value/Revenue: 3.98
• Enterprise Value/Gross Profit: 0.07
• Enterprise Value/Ebitda: -0.88
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 32 Underperform
• Price Target: ―

Pressure Biosciences' score reflects significant financial instability with high leverage and negative cash flows. The absence of positive technical indicators and valuation metrics further weighs on the stock. The lack of guidance or sentiment from the earnings call adds uncertainty, limiting any positive outlook in the near term.

Pressure Biosciences Business Overview & Revenue Model

Company Description

Pressure BioSciences, Inc. (PBIO) is a life sciences company focused on developing and commercializing innovative technologies and products for the global healthcare, biotechnology, pharmaceutical, and food industries. The company specializes in high-pressure-based scientific instruments and associated consumables, which are used for various applications, including biomarker discovery, drug design, food safety, and pathogen inactivation. PBIO's core technology platform, Pressure Cycling Technology (PCT), enables the manipulation of biomolecules and cellular structures in a unique manner, enhancing the quality and efficiency of scientific research and development.

How the Company Makes Money

Pressure BioSciences generates revenue primarily through the sale of its proprietary high-pressure instruments and consumable products. The company markets its Pressure Cycling Technology (PCT) systems to research institutions, biotechnology and pharmaceutical companies, and government entities. Revenue streams include direct sales of instruments, recurring sales of consumables required for ongoing use of the systems, and service contracts for maintenance and support of the equipment. Additionally, PBIO may engage in collaborative partnerships and licensing agreements that provide funding and the potential for milestone payments and royalties. The company's growth is supported by its focus on expanding applications for its technology across various sectors, thereby increasing its customer base and market penetration.

Pressure Biosciences Financial Statement Overview

Summary

Pressure Biosciences is facing significant financial challenges with negative net income, high debt levels, negative cash flows, and negative stockholders' equity, indicating financial instability and ongoing profitability issues.

Income Statement

Pressure Biosciences has shown some revenue growth from 2022 to 2023, but consistently negative net income and EBIT margins indicate ongoing profitability challenges. The net profit margin remains deeply negative, reflecting significant expenses relative to revenue.

Balance Sheet

The company has a negative stockholders' equity, indicating liabilities exceed assets, a concerning financial position. The high debt levels relative to equity suggest financial instability and potential difficulty in meeting long-term obligations.

Cash Flow

Operating cash flow is negative and free cash flow has not shown improvement, indicating cash generation issues. The company relies heavily on financing activities to support operations, which may not be sustainable long-term.

Breakdown	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	1.98M	1.73M	2.00M	1.22M	1.81M
Gross Profit	799.56K	-284.66K	1.06M	637.74K	612.93K
EBITDA	-9.39M	-5.40M	-5.53M	-7.46M	-6.41M
Net Income	-29.31M	-16.82M	-34.60M	-24.35M	-11.66M
Balance Sheet
Total Assets	1.05M	2.01M	2.83M	2.30M	1.82M
Cash, Cash Equivalents and Short-Term Investments	81.28K	3.87K	132.31K	18.54K	29.63K
Total Debt	22.89M	20.53M	14.64M	9.60M	7.96M
Total Liabilities	33.80M	34.70M	25.04M	19.22M	13.87M
Stockholders Equity	-32.75M	-32.69M	-22.21M	-16.92M	-12.06M
Cash Flow
Free Cash Flow	-3.19M	-4.50M	-4.99M	-4.88M	-6.35M
Operating Cash Flow	-3.19M	-4.48M	-4.87M	-4.88M	-6.33M
Investing Cash Flow	-7.50K	-20.75K	-122.94K	-796.66K	-23.38K
Financing Cash Flow	3.27M	4.37M	5.11M	5.67M	6.28M

Pressure Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TECH	76 Outperform	$8.16B	63.41	6.53%	0.61%	4.72%	-35.33%
TMO	76 Outperform	$156.57B	24.34	13.73%	0.49%	0.96%	9.19%
MDXG	74 Outperform	$948.25M	23.80	22.29%	―	5.34%	-50.52%
BIO	56 Neutral	$6.71B	―	-27.51%	―	-2.46%	-637.11%
Sector *	52 Neutral	$7.36B	-0.07	-63.77%	2.36%	16.35%	0.03%
QDEL	47 Neutral	$1.72B	―	-10.59%	―	-3.18%	81.18%
PBIO	32 Underperform	$16.39K	―	89.50%	―	-20.28%	13.56%